Clinical Trial Update: Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pre-treatment with Interleukin-2 for highly suspicious pigmented skin lesions (melanoma and melanoma in situ) was terminated; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Melanoma in Situ

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Carman Giacomantonio | Conditions: Melanoma (Skin), Melanoma in Situ | Phase 3 | Status: TERMINATED | Results posted: 2024-07-24